Nautilus Biotechnology (NAUT) SEC Filings

Nautilus Biotechnology, Inc. (NAUT) reported third-quarter 2026 revenue of $234,000 and a net loss of $15.6 million, compared with $13.6 million a year earlier. Operating expenses were $16.9 million, up 10% from $15.5 million, as higher laboratory and professional-services costs and salaries and benefits were partly offset by lower facilities expenses. Cash, cash equivalents and investments totaled $114.3 million as of September 30, 2026.

The company published a peer-reviewed Nature Methods paper on Iterative Mapping and shared initial oncology proteoform assay data, including AKT1, with a performance profile it said matched Tau. Nautilus said it advanced the proteoform pipeline for 20 assays planned through mid-2028. After quarter-end, it announced participation in SEEDS, a four-year, ARPA-H-funded research consortium, and expects to receive up to $6 million to deploy Voyager to measure proteoforms driving Alzheimer’s disease and cancer. Voyager is not yet commercially available and remains subject to significant scientific and technical development; planned instrument availability is in mid-2027.

Nautilus Biotechnology, Inc. (NAUT) has established an at-the-market equity program under its shelf registration, allowing it to sell up to $125 million of common stock from time to time through TD Securities (USA) LLC (TD Cowen) as sales agent or principal. This $125 million capacity is part of Nautilus’s existing $300 million Form S‑3 shelf.

At an assumed price of $1.12 per share, Nautilus illustrates issuance of approximately 111.6 million shares, which together with existing shares would bring total common stock outstanding up to 238,831,782 shares and increase net tangible book value from $1.03 to $1.05 per share, implying $0.07 per‑share dilution to new investors. Net proceeds, after up to 3.0% commissions to TD Cowen and estimated offering expenses, are intended for general corporate purposes and working capital, including continued development and commercialization of Nautilus’s proteomics platform. The company is a development‑stage, smaller reporting company and does not expect to pay cash dividends, so return would depend on share price appreciation.

Nautilus Biotechnology, Inc. (NAUT) is the subject of this Amendment No. 4 to a Schedule 13D, in which venture funds affiliated with Andreessen Horowitz update their ownership disclosure. The reporting entities AH Bio Fund II, L.P. and Andreessen Horowitz LSV Fund II, L.P. report holding 5,782,188 and 481,047 shares of Nautilus common stock, respectively.

Based on 127,255,223 shares outstanding as of July 24, 2026, Marc Andreessen and Benjamin Horowitz each report beneficial ownership of 6,263,235 shares, or 4.9% of Nautilus’s common stock, through these funds. Following a series of open market sales between August 31 and September 9, 2026, the reporting persons state they ceased to be beneficial owners of more than five percent of Nautilus’s common stock on September 9, 2026.

Nautilus Biotechnology, Inc. (NAUT) entered into a new Sales Agreement with TD Securities (USA), LLC on September 11, 2026 for an “at the market” offering program to sell up to $125,000,000 of common stock from time to time, with TD Cowen acting as sales agent and earning up to 3.0% of gross proceeds on shares sold. The company controls key sale parameters, may suspend or terminate the program, and is not obligated to sell any shares. The shares will be issued under a Form S-3 shelf registration statement filed the same day, after it is declared effective by the SEC. On the same date, Nautilus and TD Cowen mutually terminated their February 28, 2024 at-the-market Sales Agreement, under which no common stock had been sold.

Nautilus Biotechnology, Inc. (NAUT) has filed a shelf registration that allows it to offer and sell up to $300,000,000 of various securities, including common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts and units, in one or more future offerings.

Within this shelf, Nautilus established an at-the-market program under a sales agreement with TD Securities (USA) LLC, permitting sales of up to $125,000,000 of common stock from time to time on Nasdaq or through negotiated transactions. The $125,000,000 of common stock is part of, and not in addition to, the $300,000,000 overall shelf capacity.

The company’s independent auditor, PricewaterhouseCoopers LLP, included an emphasis of matter relating to Nautilus’s net operating losses and negative cash flows from operations in the report on the year ended December 31, 2025, highlighting management’s evaluation of related conditions. Nautilus is a development stage life sciences company focused on its Nautilus Voyager proteomics platform and qualifies as a smaller reporting company.

Nautilus Biotechnology, Inc. (NAUT) received an Amendment No. 3 to a Schedule 13D from venture funds affiliated with Andreessen Horowitz reporting updated ownership and recent trading activity in Nautilus common stock.

The filing states that AH Bio Fund II, L.P. beneficially owns 7,094,691 shares of Nautilus common stock, representing 5.6% of the class, and Andreessen Horowitz LSV Fund II, L.P. beneficially owns 590,241 shares, representing 0.5%. Marc L. Andreessen and Benjamin A. Horowitz are reported as having shared voting and dispositive power over an aggregate 7,684,932 shares, or 6.0% of Nautilus’ common stock.

The reported ownership percentages are based on 127,255,223 shares outstanding as of July 24, 2026. The funds disclose multiple open market sales of Nautilus shares between July 31 and August 27, 2026, at weighted average prices generally around $0.90–$1.05 per share, and undertake to provide full pricing breakdowns upon request.

Nautilus Biotechnology, Inc. received an updated ownership report from Perceptive Advisors and related entities. The group reports beneficial ownership of 11,634,211 shares of Nautilus common stock, representing 9.1% of the class, based on 127,255,223 shares outstanding as of July 24, 2026.

Perceptive Life Sciences Master Fund, Ltd. directly holds 11,468,351 shares, and C2 Life Sciences LLC directly holds 165,860 shares. Perceptive Advisors LLC, as investment manager to both entities, and its managing member Joseph Edelman share voting and dispositive power over these holdings, while neither Perceptive Advisors nor Edelman holds Nautilus shares directly.

Nautilus Biotechnology, a development-stage proteomics company, reported revenue of $0.2 million for the six months ended June 30, 2026, mainly from a Michael J. Fox Foundation grant and early access services. Net loss was $29.2 million, modestly better than $31.6 million a year earlier, as research and development and selling, general and administrative expenses declined 12% and 9%, respectively.

As of June 30, 2026, cash, cash equivalents and short-term investments totaled $84.0 million, and cash, cash equivalents and investments were $129.2 million. Management believes this will fund operations for at least 12 months. The company has a $125.0 million at-the-market equity program and a $300.0 million shelf registration. Nautilus continues developing its Nautilus Voyager proteomics platform, has launched an Iterative Mapping Early Access Program focused on Tau and other proteoforms, and plans a phased commercial launch with pre-orders in early 2027 and instrument shipments in mid-2027.